By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Response Biomedical this week said that it has consolidated its stock on a 10 for one basis. The Vancouver, BC-based molecular diagnostics company said that the consolidation applies to all of its common shares, stock options, and warrants. Following the consolidation, Response Biomedical has 25,467,200 common shares outstanding.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.